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SUMMARY—Intestinal microbial metabolites are conjectured to affect mucosal integrity through
an incompletely characterized mechanism. Here we showed microbial-specific indoles regulated
intestinal barrier function through the xenobiotic sensor, pregnane X receptor (PXR). Indole 3-
propionic acid (IPA), in the context of indole, is as a ligand for PXR in vivo, and IPA down-
regulated enterocyte TNF–α while up-regulated junctional protein-coding mRNAs. PXR-deficient
(Nr1i2−/−) mice showed a distinctly “leaky” gut physiology coupled with up-regulation of the
Toll-like receptor (TLR) signaling pathway. These defects in the epithelial barrier were corrected
in Nr1i2−/−Tlr4−/− mice. Our results demonstrate that a direct chemical communication between
the intestinal symbionts and PXR regulates mucosal integrity through a pathway which involves
luminal sensing and signaling by TLR4.
INTRODUCTION
Intestinal luminal contents (e.g., bacteria, food, metabolic by-products) are known to
influence the gut barrier function through immune recognition (Clemente et al., 2012;
Salzman, 2011). However, specific effects of microbial luminal metabolites on regulating
epithelial innate immune homeostasis (e.g., epithelial barrier function) is incompletely
characterized (Ashida et al., 2011). Indeed, disruption of epithelial barrier function is now
emerging as an important mediator of intestinal inflammation (e.g., inflammatory bowel
disease) (Fasano and Shea-Donohue, 2005; Maloy and Powrie, 2011; Xavier and Podolsky,
2007) as well as organ pathophysiology (e.g., allergy, diabetes, obesity, heart disease,
arthritis, cognitive defects) (Gummesson et al., 2011; Islam and Luster, 2012; Mayer, 2011;
Meier and Plevy, 2007; Turner, 2009).
Given that there are approximately 100 trillion bacteria in the intestines, their metabolic by-
products and chemical repertoire are likely to be important mediators of as yet to be defined
host phenotype (Rath and Dorrestein, 2012). Indeed, while dietary constituents have been
shown to regulate barrier function, discrete mechanisms of microbial metabolites that
regulate intestinal epithelial integrity remains elusive (Leavy, 2011). As adopted orphan
nuclear receptors are known signaling intermediates for certain host-bacterial metabolites
(e.g., bile acids and farnesoid x receptor (FXR), dietary ligands and aryl hydrocarbon
receptor (AhR), we focused on pregnane X receptor (PXR), since its promiscuous ligand
binding pocket might well be capable of accomodating diverse small bacterial metabolites
(Watkins et al., 2001).
To test the hypothesis that elements of the host environment, (i.e. symbiotic bacteria)
regulate intestinal barrier function through PXR, we focused on exploring the functions of
indole metabolites (e.g., Indole 3-propionic acid, IPA), that are exclusively produced by
intestinal commensal microbes (Wikoff et al., 2009). In mice, IPA synthesis appears linked
to the intestinal commensal Clostridium sporogenes (Wikoff et al., 2009). In humans under
homeostatic conditions, blood IPA and indole concentrations remain in micromolar and
millimolar range, respectively, with intestinal concentrations predicted to be much higher
(Bansal et al., 2010). To-date the cellular target of IPA remains elusive. To determine
whether IPA could potentially regulate intestinal barrier function through PXR, we
performed a combination of in vitro, ex vivo and in vivo studies of the effect of IPA on
epithelial permeability and inflammation. The results showed that IPA (in the presence of
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indoles) served as a likely physiologic ligand for PXR and down-regulated enterocyte
mediated inflammatory cytokine tumor necrosis factor-α (TNF-α) while up-regulating
junctional protein-coding mRNAs. PXR-deficient (Nr1i2−/−) mice exhibited a distinctly
“leaky” intestinal epithelium pathology, whereas replacing PXR using bone marrow
chimeras established that PXR must be present in non-hematopoietic compartments for
normal intestinal inflammatory signals and barrier functions. Importantly, Nr1i2−/− intestinal
cells exhibited up-regulation of toll-like receptor 4 (TLR4). These molecular events, as well
as overall defects in the epithelial barrier, were corrected in Nr1i2−/−Tlr4−/− mice.
Collectively, these results demonstrate that a direct chemical communication between the
gastrointestinal symbionts and a specific nuclear receptor pathway, control mucosal
homeostasis.
RESULTS
Symbiotic intestinal bacteria derived IPA regulates intestinal permeability and
inflammation through PXR
To simulate in vivo homeostatic conditions, we activated PXR using a combination of indole
with its respective metabolites. Although IPA alone was a weak human PXR (hPXR)
agonist (EC50 120 μM, Emax 6.38 fold over control) (Figure 1A); IPA in combination with
indole significantly activated hPXR (Figure 1B). Similar results were observed with indole 3
acetic acid (IAA) (Figures S1A) and supported by in silico docking studies (Figure S1B;
Table S1; Figure S1C). In contrast, mouse PXR (mPXR) was potently activated by IPA
(EC50 0.55 μM, Emax 18.84 fold over control) in vitro (Figure 1A) and induced PXR target
gene transcription in vivo (Figure 1C; Figure S1D). More importantly, as specific indoles
have been shown to activate the AhR (Denison and Nagy, 2003), we were unable to
demonstrate activation of AhR by IPA (Figure S1E).
We next examined effect of indoles on enterocyte inflammatory signals and barrier function.
Importantly, differences between Nr1i2−/− and Nr1i2+/+ mice were maintained when
specifically assaying small intestinal permeability in vivo (Figures S1F and S1G) as well as
using an in vivo multi-photon intravital microscopy (Figure S1H and supplemental movies
S1 and S2).
For critical validation of the ex vivo experiments demonstrating IPA effects on junctional
regulators, we co-administered C. sporogenes to germ-free mice in the presence or absence
of L-tryptophan (Figure 1D). We verified that C. sporogenes inoculation led to production
of IPA in vivo (thus, it was assumed that indoles were present) (Figure 1E). Germ-free mice
exposed to C. sporogenes had a significant reduction in FITC-dextran recovery from the
serum and this was further reduced in the presence of L-tryptophan dosing (Figure 1F). The
mice intestinal mucosa exposed to C. sporogenes demonstrated significant induction of PXR
target genes (Mdr1, Cyp3a11, Ugt1a1), which was further augmented in the presence of L-
tryptophan (Figure 1G).
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IPA regulates intestinal inflammation through PXR
To validate that IPA was driving the anti-inflammatory response in vivo directly via PXR,
we exposed intestinal commensal-depleted Nr1i2+/+ and Nr1i2−/− mice to live or heat-killed
C. sporogenes. All mice were subsequently exposed to indomethacin (Figure 2A). We
verified that only live C. sporogenes, but not the heat-killed bacterial inoculation, led to
production of IPA in vivo (Figure 2B). There was a significant reduction in the histologic
injury and in mucosal myeloperoxidase (MPO) enzyme activity in Nr1i2+/+ but not in
Nr1i2−/− mice (Figures 2C and 2D). Furthermore, in these mice, intestinal mucosa exposed
to the C. sporogenes had significant induction of PXR target gene (Ugt1a1) when compared
to mice exposed to the heat-killed strain (Figure 2E). No such effects were observed in
Nr1i2−/− mice (Figures 2B-2E).
The effects of C. sporogenes in vivo was directly validated using IPA administration by the
oral route in both Nr1i2+/+ and Nr1i2−/− mice. Although IPA effects could be non-target
dependent based on the concentrations administered (i.e. non-specificity of molecular targets
based on the concentration of IPA), we chose to study at fixed dose of IPA using an
inflammation-based barrier defect (indomethacin) model. In this model, Nr1i2+/+ and
Nr1i2−/− mice were administered IPA followed by indomethacin and intestinal permeability
assessed. The rationale was that a defect in permeability was required in order to show the
effect of IPA in both the wild-type and Nr1i2−/− mice. IPA dosing significantly reduced
FITC-dextran permeability in Nr1i2+/+ (Figure 2F) but not in Nr1i2−/− mice (Figure 2G).
In an in vivo model of 3-deoxy-D-manno-octulosonic acid (KDO2)-lipid A (TLR4 ligand)
intubation, which elicits inflammatory signals without disrupting the intestinal tissue
architecture (see experimental procedures), there was no overt histologic evidence of
inflammation (Figure S2A). However, TNF-α mRNA (Figure S2B), p38-MAPK
phosphorylation (Figure S2C), and permeability to FITC-dextran (Figure S2D), were clearly
induced after KDO2 treatment. In this model, at IPA concentrations that were achievable
through oral gavage (Figure S2E), we found that IPA notably decreased TNF-α mRNA
expression more in the Nr1i2+/+ mice (3.73 fold) intestinal epithelium relative to Nr1i2−/−
mice (1.72 fold) (Figure S2F). Together, these studies and the effects of IPA depletion in
vivo (see Table S2; Figures S2G-S2I) establish PXR as an important enterocyte target of
IPA.
Nr1i2−/− mice exhibit enhanced ultrastructural defects that directly correlate with increased
intestinal permeability and xenobiotic toxicity
To study the function of PXR under steady-state conditions, we performed detailed
histological analysis using 6-8 week old Nr1i2−/− and Nr1i2+/+ mouse intestines. Although
gross features appeared unchanged, histological examination of the mucosa of Nr1i2−/−
mice small intestines showed significant diminution of the villus-crypt ratio (Figure S3A),
marked neutrophil infiltration and increased MPO enzyme activity (Figure S3B). The data
shown compare the jejunum (highest expression of PXR in the intestine) of Nr1i2+/+ and
Nr1i2−/− mice; data pertaining to other regions (i.e. duodenum, ileum) have similar trends
(data not shown). Although subtle, these differences indicate that the small intestine of
Nr1i2−/− mice may persist in a state of mild elevated stress that may culminate as overt
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inflammation when exposed to injurious insults. Indeed, we did not observe any significant
changes in unfolded protein response (UPR) genes (UPR RT2 ProfilerPCR Array,
SABiosciences); however, a single gene, Serp1 mRNA, was induced 27-fold in Nr1i2−/− as
compared with Nr1i2+/+ mouse intestinal mucosa (data not shown). The induction of Serp1
could act to stabilize membrane glycoprotein and stabilize their signaling (e.g., TLR4)
(Yamaguchi et al., 1999). In keeping with the mild state of intestinal stress, defects observed
in Nr1i2−/− mice are not due to any gross changes in proliferation (BrdU) or apoptosis
(TUNEL) of the epithelium (Figure S3C).
To investigate whether PXR deficiency sensitizes mice to toxic insults, we subjected
Nr1i2−/− and Nr1i2+/+ mice to four toxic intestinal injury models. In the indomethacin-
induced (85 mg/kg body weight, ip, single dose) small intestine inflammation model, the
Nr1i2+/+ mice exhibited modest inflammation by histology (Figure 3A) and in jejunal MPO
activity (Figure 3B). In contrast, the Nr1i2−/− mice showed significantly enhanced basal
MPO activity, which increased upon indomethacin treatment (Figure 3B). In evaluating the
histology in Nr1i2−/− mice, the histologic score increased by 6.2 fold over that observed in
Nr1i2+/+ mice (Figure 3C). In the anti-CD3 antibody induced intestinal inflammation-
edema model, mice were exposed to anti-CD3 (clone 2C11, 200 μg ip) and tissues harvested
3 hours later for enteropooling. Notably, 100% of Nr1i2−/− mice given this dose of anti-
CD3 antibody succumb to intestinal edema and died within 72 hours of dosing. Indeed,
small bowel isolated after 24 hours of dosing with anti-CD3 antibody showed the mean
values of enteropooling did not exceed 30 mg/cm (maximum value obtained ~ 31.5 mg/cm),
suggesting that enteropooling values saturate around ~ 30-31 mg/cm (Musch et al., 2002).
Although the changes in enterpooling values were not significantly different, it is clear that
the Nr1i2−/− mice have increased susceptibility to anti-CD3 mediated injury based on the
observation that the mean enteropooling values have maximized ~ 29.5 mg/cm (maximum
value ~ 31.5 mg/cm) (Figure 3D). Therefore, the true increase in enteropooling is capped by
saturated values in the anti-CD3 treated Nr1i2−/− mice. In addition, there was near complete
blunting of crypt-villus architecture in Nr1i2−/− as compared to Nr1i2+/+ mice (Figure 3E).
In the gastrointestinal ischemia-reperfusion model (I/R), the endogenous lectin complement
pathway is a key initiator of intestinal inflammation in which the intestinal epithelium plays
an important role in mediating such damage (Hart et al., 2005). An early finding that persists
and then worsens with prolonged ischemia-reperfusion is intestinal barrier dysfunction as
manifested by changes in intestinal permeability (Hart et al., 2005). We assessed FITC-
dextran recovery after oral gavage of Nr1i2+/+ and Nr1i2−/− mice. The change in
permeability as assessed by a change in recovery of mean levels of FITC-dextran in the
serum of mice for Nr1i2+/+ and Nr1i2−/− was 193% and 488.9% (Figure 3F), respectively.
These results suggest that the Nr1i2−/− mice are significantly more susceptible to ischemia-
reperfusion mediated changes in intesinal barrier function. Finally, we used an endotoxic
shock model, whereby systemic LPS induces a sepsis like syndrome which prominently
features intestinal barrier dysfunction (Roger et al., 2009). Nr1i2−/− mice treated with LPS
had significantly worse survival than its Nr1i2+/+ counterpart suggesting that the loss of
PXR significantly worsens survival in LPS-mediated septic syndrome, in which intestinal
dysfunction plays a major role (Figure 3G). The LPS findings corroborate previous
observations that PXR protects against LPS mediated liver damage (Wang et al., 2010).
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Together, Nr1i2−/− mice demonstrate heightened sensitivity towards all four direct and
indirect toxic intestinal injury models (Figure 3) (Clayburgh et al., 2005; Ettarh and Carr,
1996; Zhou et al., 2006). The lack of significant steady-state gross inflammatory pathology
in Nr1i2−/− mice, contrasts with this heightened sensitivity towards xenotoxic challenge. To
reconcile these findings, we performed ultra-structural and biochemical analysis of Nr1i2+/+
and Nr1i2−/− mice jejunal epithelium. Transmission electron microscopy (TEM) of
Nr1i2−/− mice intestinal epithelial cells showed loosely packed shorter microvilli relative to
Nr1i2+/+ mice (Figures 4A and 4B). Additionally, Nr1i2−/− mice microvilli show
significantly diminished digestive enzyme activities compared to Nr1i2+/+ microvilli
(Figure 4C), and the activity (Figure 4D) and abundance (Figure 4E) of alkaline phosphatase
is also notably reduced in the Nr1i2−/− mice intestine. Together, these data demonstrate that
key aspects of the fine structure and enzyme expression in the Nr1i2−/− mice intestine
would explain its enhanced sensitivity towards xenobiotic challenge (Matsui et al., 2011).
We next examined the cell-cell junctional complex, an essential structural component of the
epithelial barrier. TEM showed that the tight-junction (Tj) and adherens-junction (Aj)
complex (black arrow) in Nr1i2−/− mice intestinal epithelium to be significantly more
electron dense, diffuse with dense interconnected stranding (Figure 4F). The mRNA
expression of these key junctional-complex markers were markedly diminished in the
Nr1i2−/− mice, except Claudin-2 which is known to induce barrier defects (Figure 4G) (Van
Itallie and Anderson, 2006). Immunofluorescence showed similar trends (Figure S4A and
S4B). Furthermore, in comparison with Nr1i2+/+ mice, there is increased FITC-dextran
recovery in serum (Figure 4H). Together, these ultra-structural and functional assays
implicate PXR as a physiologic regulator of intestinal barrier function.
TLR4 signaling is an essential causative pathway in the epithelial barrier defects observed
in the Nr1i2−/− mice
To screen for molecular mechanisms that are responsible for barrier dysfunction in Nr1i2−/−
mice, we determined relative abundance of key host mRNAs encoding proteins involved in
inflammation and microbial invasion. We performed real-time qPCR for anti-inflammatory,
anti-microbial and pro-inflammatory markers using total RNA isolated from Nr1i2+/+ and
Nr1i2−/− mice villi enterocytes. In the Nr1i2−/− mice, there is a significant down-regulation
of mRNAs involved in anti-inflammatory and anti-microbial function, along with a
concomitant increase in pro-inflammatory cytokine mRNAs (Figure 5A). Given that TLRs
are critical regulators of intestinal barrier function as well as inflammation, we chose to
focus on them (Asquith and Powrie, 2010). We performed real-time qPCR for all ten
mammalian (mouse) TLRs. TLR over-expression was modest (1.2 to 1.8 fold) and variable
(Figure 5B); however, downstream TLR pathway kinase activation was enhanced in
Nr1i2−/− mice (Figure S5A). Among the TLRs, TLR2 and 4 are expressed on the villi
enterocytes and play significant roles in the regulation of intestinal barrier function (Cario,
2010). To identify the TLRs that may affect inflammatory cytokine mediated barrier
function in Nr1i2−/− mice, we incubated Nr1i2−/− enterocytes ex vivo with TLR2 and 4
inhibitors. TLR2 inhibition increased TNF-α and IL-6 mRNA expression in the intestinal
mucosa of Nr1i2−/− mice, conversely, TLR4 inhibition significantly suppressed cytokine
mRNA expression (Figure S5B). Furthermore, we generated Nr1i2−/−Tlr2−/− mice and
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mucosa extracted from these mice show increased Tnf-α and Il-6 mRNA expression when
compared to Nr1i2−/− (Figure S5C). These findings correlates with the observation that the
loss of Tlr2 in Nr1i2−/− increased intestinal permeability (Figures S5D-S5F).
We focused next on TLR4 because it is a critical determinant of LPS signaling in the
intestine (Abreu et al., 2001). The basal expression of TLR4 protein was modestly elevated
(~1.8 fold) in Nr1i2−/− (Figure 5C) and we also observed an inverse relationship between
Pxr and Tlr4 mRNA expression in an intestinal cell line, Caco-2 (data not shown) and
primary human intestinal mucosa (data not shown). To study the role of TLR4 in barrier
dysfunction in Nr1i2−/− mice, we crossed the Nr1i2−/− with Tlr4−/− mice. In comparison
with Nr1i2−/− mice, the abundance of mRNAs encoding key Tj, Aj proteins, pro- and anti-
inflammatory cytokines were reversed in Nr1i2−/−Tlr4−/− mice epithelium to levels
comparable to those observed in Nr1i2+/+ mice (Figure 5D).
Since these markers encode for proteins involved in epithelial junctional complex formation
and inflammation, we speculate that TLR4 is indeed responsible for the barrier dysfunction
observed in Nr1i2−/− mice. To validate this hypothesis, we assessed if the magnitude of Tnf-
α mRNA expression and FITC-dextran permeability was Tlr4 gene-dose dependent. We
generated Tlr4 heterozygotes (at least ~50% reduction in protein) in Nr1i2−/− mice
background (data not shown). Enterocyte Tnf-α mRNA expression and FITC-dextran
recovery had similar quantitative reduction (Figures S5G and S5H). To further validate our
observations regarding genes encoding junctional complex proteins, we performed TEM and
immunofluorescence studies. The Nr1i2−/− Tlr4−/− mice have microvilli lengths that were
larger than Nr1i2−/− mice and comparable to that observed in Nr1i2+/+ mice (Figure 5E).
Indeed, the same trend was observed in the ultra-structure of the junctional complex (Figure
5F) and immunofluorescence staining for Zo-1 and E-cad (Figures S5I and S5J). The
activities of brush border enzymes (Figure 5G) and FITC-dextran permeability (Figure 5H)
in the Nr1i2−/−Tlr4−/− mice was also similar to that observed in Nr1i2+/+ mice.
Additionally, Nr1i2−/−Tlr4−/− mice displayed significantly attenuated damage response to
indomethacin (Figure 6A and 6B). Together, these studies show that Tlr4 is essential to
maintain epithelial barrier defects observed in the Nr1i2−/− mice.
IPA protects against indomethacin induced intestinal injury via PXR and TLR4
To further validate the requirement for TLR4 as a critical determinant of the effects of
microbiota-derived PXR ligand, IPA, Tlr4+/+ and Tlr4−/− mice were exposed to IPA
followed by indomethacin (as previously described for experiments with Nr1i2+/+ and
Nr1i2−/− mice). The results demonstrate that the presence of Tlr4 is required IPA-induced
changes in permeability defects induced by indomethacin (i.e. IPA significantly reduces
FITC-dextran permeability induced by indomethacin) (Figure 6C). Indeed, to directly
validate that the entire loop driven by microbiota-derived IPA results from modulation of
TLR4 which in turn regulates intestinal permeability, Nr1i2+/+ mice were commensal
depleted for 15 days and/or followed by exposure to TLR4 ligand, KDO2 and/or IPA
delivered orally (Figure 6D). The results demonstrate that commensal depletion increased
intestinal permeability, which was further worsened by ~2.8fold with the addition of the
TLR4 ligand, KDO2. Note, in conventional Nr1i2−/− mice possessing intact intestinal
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microbiota (i.e. LPS), the FITC-dextran recovery in blood was ~ 856 μg/ml (Figure 4H)
which is actually lower than commensal depleted Nr1i2+/+ mice exposed to KDO2 (~ 1495
μg/ml) (Figure 6D). In commensal depleted Nr1i2+/+ mice, reconstitution of mice with IPA
results in a significant decrease in permeability. These results further validate our hypothesis
that loss of microbiota producing IPA can induce a Nr1i2−/− like (not identical) state,
whereby, the presence of a TLR4 ligand, KDO2, worsens intestinal permeability and is only
corrected when IPA is reconstituted in Nr1i2+/+ mice (Figure 6D) but not in Nr1i2−/− mice
(Figure 2F&G). Finally, to understand whether the initial signals leading to disruption of the
epithelial barrier originates via hematopoietic or non-hematopoietic cells (e.g.,
predominantly the epithelium), we performed bone marrow chimera experiments between
Nr1i2−/− and Nr1i2+/+ mice. These studies clearly show that immune reconstitution with
either Nr1i2+/+ or Nr1i2−/− hematopoietic cells have no effect on pro-inflammatory markers
and intestinal permeability to FITC-dextran (Figures 7A-7C). Indeed, since intestine homing
hematopoietic derived cells are major source of cytokines that disrupt barrier function (e.g.,
TLR4 signaling), it should be stated that PXR negatively regulates TLR4 bone marrow
derived macrophages or mononuclear cells (data not shown). We saw no changes in serum
FITC-dextran recovery, Tnf-α or Il-6 mRNA in Nr1i2+/+ and Nr1i2−/− mice transplanted
with either Nr1i2−/− or Nr1i2+/+ bone marrow, respectively (Figures 7A-7C). In order to
further determine if there was any contribution by TLR4 signals emanating from
hematopoietic derived cells within the intestine, we derived combinatorial chimeric strains
harboring loss or gain of TLR4 protein in these cells resident in Nr1i2+/+ or Nr1i2−/− mice.
Nr1i2+/+ mice harboring either a gain or loss of TLR4 protein in bone marrow derived cells
within the intestine (LP cells) showed similar levels of serum FITC-dextran recovery as well
as Tnf-α or Il-6 mRNA, respectively. Nr1i2−/− mice expressing non-hematopoietic TLR4
and harboring either a gain or loss of TLR4 protein in bone marrow derived cells within the
intestine (LP cells) showed no significant difference in serum FITC-dextran recovery or
Tnf-α or Il-6 mRNA levels. Similar results were obtained in Nr1i2−/− mice with loss of non-
hematopoietic TLR4 and harboring either a gain or loss of TLR4 protein in bone marrow
derived cells within the intestine (LP cells) (Figures 7D and 7E). This effectively shows that
bone marrow derived TLR4, a major LPS-responsive effector of Tnf-α, is unable to alter the
intestinal phenotype induced by non-hematopoietic tissue. Thus, PXR resident in the non-
hematopoietic compartment (i.e., epithelium) is important in dictating the initial response to
external cues inciting epithelial barrier dysfunction.
DISCUSSION
The regulation of the intestinal barrier by intestinal commensal bacteria has been alluded to
in several important reviews on this topic (Abreu, 2010; Salzman, 2011; Wells et al., 2011).
However, thus far few discrete mechanisms have emerged (Abreu, 2010; Chen et al., 2010;
Kelly et al., 2004; Patel et al., 2012). Our data supports the role that PXR is an essential
regulator of intestinal barrier effects under conditions of homeostasis. The four models of
bowel injury, as well as evidence of chronic subclinical inflammation under basal conditions
(Zhou et al., 2006), suggests that PXR is an essential modifier of innate immunity in the
intestine and its response to xenobiotic injury. Both these elements can be tied to intestinal
barrier function, which is clearly aberrant in Nr1i2−/− mice (Matsui et al., 2011; Zhou et al.,
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2006). Bone marrow chimera studies indicate that neither Nr1i2+/+ or Nr1i2−/− bone
marrow alters expression of Tnf-α, Il-6 and FITC-dextran recovery in mice of the opposite
genotype, which strongly indicates that PXR expression in the non-hematopoietic
compartment determines the epithelial phenotype. Since PXR is expressed predominantly in
epithelial but not mesenchymal cells (Bookout et al., 2006) it is logical to conclude that the
state of activation of epithelial PXR is paramount in determining the initial events leading to
the observed intestinal barrier phenotype. Indeed, villus expression of PXR within the
intestinal mucosa, puts this receptor in nearest contact with the bacterial commensals in the
lumen. A notable caveat in our experiments was that in order to demonstrate the plausibility
that indoles would have a physiologic target in vivo, we performed all our experiments using
ex vivo systems (i.e. intestinal tissues incubated in OLA rather than in vivo administration).
These experiments were performed ex vivo to circumvent the inherent problem associated
with a perfect drug like OLA (PubChem, ST093573) which will likely be absorbed almost
completely by mucosal surfaces thus precluding efficient luminal delivery. In this context,
germ-free mice (either gnotobiotic or axenic) would not be ideal experiments since only
specific gut bacteria produce indoles and its metabolites (e.g., C. sporogenes in mice)
(Wikoff et al., 2009). The exact species producing indoles and its metabolites in humans
remain unknown; however, C. sporogenes is a soil bacterium present in humans and germ-
free mice replete with this bacterium do show alterations in intestinal barrier function.
Indeed, these results are consistent with and extend prior observations that germ-free mice
reconstituted with conventional intestinal microbes, significantly increase liver PXR and its
target gene, Cyp3a11 expression (Claus et al., 2011). We have performed microbial
reconstitution experiments in commensal-depleted mice that have validated our ex vivo
observations that bacterial indoles (in particular IPA) directly affect intestinal barrier
properties in vivo through actions mediated via PXR.
Our data implicate epithelial PXR as a central regulator of TLR4 mediated control of the
intestinal barrier function. This regulation is intrinsically associated with intestinal
commensals, specifically those involved with the metabolism of tryptophan and production
of indoles and specific metabolites (i.e. IPA). We hypothesize that this association is tightly
regulated to ensure “fine-tuning” of TLR4 expression in the intestine at levels appropriate to
the abundance of LPS and perhaps other microbial-derived ligands. For homeostasis, all
three components of this system (indole secreting intestinal commensals, epithelial PXR
expression, and TLR4) must be at appropriate levels for a given host – a lack of IPA or PXR
or an excess of TLR4 can lead to intestinal barrier dysfunction. In fact, compromised
intestinal barrier function has been implicated in the pathogenesis of several disease states
(e.g., type I diabetes, asthma, autism, acne, allergies etc.) including inflamatory bowel
disease (IBD) (Gummesson et al., 2011; Islam and Luster, 2012; Mayer, 2011; Meier and
Plevy, 2007; Turner, 2009). Hence, search for effective treatment options to prevent
intestinal epithelial barrier defects may have broader implications beyond IBD.
Moreover, our data in epithelial cells complement parallel nuclear receptor driven pathways
in intestinal immune cells that regulate barrier function (Kelly et al., 2004; Leavy, 2011). It
adds a new dimension to recent observations that the intestinal epithelial homeostasis is
tightly orchestrated by the circadian clock (e.g., RevErbα) as well as microbiota transduced
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by TLRs (Mukherji et al., 2013) and that bacterially derived uracil serve as modulators of
mucosal immunity and intestine-microbe homeostasis in Drosophila (Lee et al., 2013).
Metabolomic analysis have identified low levels of tryptophan in Il10−/− mice and its host-
derived kyneurenine metabolite levels are elevated. These observations have led to the
hypothesis that the kynurenine metabolites might be involved in the regulation of immune
tolerance towards intestinal microbiota by inducing Treg differentiation that produce IL10
(Lin et al., 2010). Furthermore, plasma tryptophan levels are reduced in patients with
Crohn’s disease (Gupta et al., 2012; Hisamatsu et al., 2012). Interestingly, fecal tryptophan
levels are elevated in patients with Crohn’s disease, suggesting perhaps that tryptophan
metabolism is blunted in the microbiota of these patients (Jansson et al., 2009). In keeping
with this notion of reduced tryptophan metabolism, indoxyl sulphate (product of indole
metabolism by bacteria) is reduced in mice exposed to DSS (Dong et al., 2013) and IPA is
significantly reduced in the H. hepaticus colitis model in Rag2−/− mice (Lu et al., 2012).
Furthermore, patients with HIV infection demonstrate an inverse correlation of serum IPA
and LPS (marker of intestinal microbial translocation) supporting the view that IPA
regulates intestinal permeability in humans (Cassol et al., 2013). These observations are
consistent with the notion that altered bacterial amino acid metabolism correlates with
intestinal homeostasis (Martin et al., 2008). Thus, taken together, these observations provide
important chemical biology steps toward a more comprehensive understanding of intestinal
barrier function.
EXPERIMENTAL PROCEDURES
Cell lines and reagents
The human colon cancer cell lines (Caco-2 and LS174T) and 293T cells were obtained from
the American Type Culture Collection (ATCC) and cultured according to ATCC
recommendations. For further details refer Supplemental Experiemental Procedures.
Mice
Tlr4−/− (B6.B10ScN-Tlr4lps-del/JthJ, stock number 007227), Tlr2−/− (B6.129-Tlr2tm1Kir/J,
stock number 004650) and C57BL/6J (stock number 000664) mice were obtained from the
Jackson Laboratory (Bar Harbor, ME). Swiss Webster (SW, control) and Swiss Webster
Germ Free (SWGF) mice (7-8 weeks old, female) were purchased from Taconic (Hudson,
NY). All animal experiments were approved by the animal institute committee (protocol #
20070715, 20100711) of the Albert Einstein College of Medicine and were performed in
accordance with institutional and national guidelines. For further details refer Supplemental
Experiemental Procedures.
Genotyping
Mouse tail DNAs were used for genotyping according to manufacturer’s instructions
(DNeasy Blood and Tissue kit, Qiagen). Primer sequences and methods are in Supplemental
Experiemental Procedures.
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Histology and Immunofluorescence analysis
Intestinal tissue sections (paraffin and frozen) were prepared and Hematoxylin-eosin
staining were performed in the Histology core facility of Albert Einstein College of
Medicine. Histological scoring was performed according to previously published methods
(Asano et al., 2009). Experimental details in Supplemental Experiemental Procedures.
Isolation of small intestine villi enterocytes
We have employed the modified Weiser method to isolate pure villus enterocytes from the
jejunum in all mice experiments as previously published (Weiser, 1973). Details in
Supplemental Experiemental Procedures.
In vitro transcription assay
Experimental details in Supplemental Experiemental Procedures.
Oral dosing of IPA
Nr1i2+/+ and Nr1i2−/− mice were gavaged with 10, 20 and 40 mg/kg IPA, dissolved in
sterile PBS (pH 7.4) in 100 μl volume per mice for four consecutive days. Swiss Webster
(SW) and Swiss Webster Germ Free (SWGF) mice were orally gavaged with 20 mg/kg IPA
for four consecutive days.
Transmission electron microscopy
Experimental details in Supplemental Experiemental Procedures.
Enzyme activity assay
Experimental details in Supplemental Experiemental Procedures.
Tissue myeloperoxidase (MPO) activity assay
Experimental details in Supplemental Experiemental Procedures.
In vivo intestine permeability assay
Experimental details in Supplemental Experiemental Procedures.
Germ free mice
Experimental details in Supplemental Experiemental Procedures.
Commensal depletion
Experimental details in Supplemental Experiemental Procedures.
Real-Time Quantitative RT-PCR
Experimental details in Supplemental Experiemental Procedures.
Immunoblot
Experimental details in Supplemental Experiemental Procedures.
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Tandem mass spectrometry (LC/MS/MS)
Experimental details in Supplemental Experiemental Procedures.
In vivo toxic small intestine injury models
For indomethacin induced mouse jejunitis model, we have modified a protocol published by
Ettarh and Carr by using a single intraperitoneal dose of indomethacin to reduce the toxicity
in Nr1i2−/− mice (Ettarh and Carr, 1996). Details in Supplemental Experiemental
Procedures.
Bone marrow transplantation
Experimental details in Supplemental Experiemental Procedures.
BrdU and TUNEL staining
Experimental details in Supplemental Experiemental Procedures.
TLR2 and 4 inhibition experiments
Experimental details in Supplemental Experiemental Procedures.
Intravital imaging of the intestines
Experimental details in Supplemental Experiemental Procedures.
Lenti-based shRNA knock-down systems
Details of the procedure can be found in the recent publication by our laboratory (Wang et
al., 2011).
Statistical analysis
Data are shown as mean ± s.e.m. The significance of difference was analyzed by two-tailed
Student’s t-test or ANOVA with post-hoc tests were used as indicated. The Kaplan-Meier
method was used for survival and differences were analyzed by the log rank test (Figure
3G). All analyses were performed using GraphPad PRISM version 6.01 (GraphPad
Software). P < 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Commensal derived indole metabolite, IPA, regulates PXR activation
(A) Transcriptional activity of a PXR reporter gene (multi-drug resistance-associated protein
2 or MRP2 luciferase) co-transfected with mPXR (black) and hPXR (red) expression
plasmids in 293T cells following treatment with IPA (n=3). RLU, relative light unit.
(B) Transcriptional activity of a PXR reporter gene (MRP2 luciferase) co-transfected with
hPXR expression plasmid in 293T cells following treatment with fixed concentration of
indole (1 mM) and increasing concentrations of IPA (n=3). RLU, relative light unit. Data
expressed as fold change in RLU compared to vehicle (DMSO) controls.
(C) Real-time qPCR analysis of Mdr-1 expression in Nr1i2+/+ and Nr1i2−/− mice jejunum
villi enterocytes following oral treatment with IPA (20 mg/kg/day) (n=5 per group). *P ≤
0.0001; **P ≤ 0.001;n.s. not significant (Two-way ANOVA with Tukey’s multiple
comparison test).
(D) Schematic of germ free mouse treatment schedule. Six treatment groups are shown by
color code: Swiss Webster Germ Free mice (SWGF) group, administered 100 μl LB and 100
μl sterilized water by oral gavage; SWGF + tryptophan (Trp) group, administered 100 μl LB
+ L-tryptophan; SWGF + Heat-killed C. sporogenes (C.s) group, administered C.s by oral
gavage; SWGF + (C.s) group, administered C.s by oral gavage; SWGF + Heat-killed (C.s) +
Trp group; and SWGF + C.s + Trp group, administered C.s and Trp by oral gavage (see
Experimental Procedures). All the treatments were scheduled for six sequential days.
(E) Plasma IPA peak area intensity values plotted by treatment group as illustrated in the
schema (D) Color coded histograms show mean ± s.e.m. values pertaining to each treatment
group. IPA concentrations in micromoles (μM) are listed by color code.
(F) erum FITC-dextran recovery in treatment groups illustrated in schema (D).
*P ≤ 0.0001; (Two-way ANOVA with Tukey’s multiple comparison test ); (n=6 per group).
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(G) Real-time qPCR analysis of Mdr1, Cyp3a11 and Ugt1a1 mRNA expression in small
intestinal mucosa from schema (D). All graphs show mean values ± s.e.m. Also see Figure
S1,Table S1 and supplemental movies S1 and S2.
Venkatesh et al. Page 17






















Figure 2. Commensal C. sporogenes reconstitution decreases intestinal permeability and
inflammation in a PXR-dependent manner in mice
(A) Schematic of commensal depletion and C. sporogenes reconstitution experiment in
Nr1i2+/+ and Nr1i2−/− mice (see Experimental Procedures).
(B) Plasma IPA peak area intensity values plotted by treatment groups as illustrated in the
schema (A). The IPA concentrations in micromoles (μM) pertaining to each group is
illustrated above each histogram.
(C) Hematoxylin and eosin staining of C. sporogenes + L-tryptophan and Heat killed C.
sporogenes + L-tryptophan exposed Nr1i2+/+ and Nr1i2−/− mice jejunum cross-sections in
accordance with schema (A). Scale bars, 50 μm.
(D) Jejunal MPO activity (unit/g of total protein) in treatment groups from schema (A) as
illustrated.
(E) Real-time qPCR analysis of Ugt1a1 mRNA expression in small intestinal mucosa from
schema (A).
(F and G) Serum FITC-dextran recovery following oral gavage of IPA (20 mg/kg/day) and
indomethacin (see schematic) in (F) Nr1i2+/+ (n = 9) and (G) Nr1i2−/− (n = 9) mice.
All graphs show mean values ± s.e.m. *P ≤ 0.01 (Two-way ANOVA with Sidak’s multiple
comparison test); (n=6 per group). **P ≤ 0.01 (Student’s t-test); n.s. not significant. Also see
Figure S2 and Table S2
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Nr1i2−/− mice are more susceptible to toxic injuries to the small intestine
(A) Hematoxylin and eosin staining of indomethacin (Indo) treated Nr1i2+/+ and Nr1i2−/−
mice jejunum cross-sections.
(B) Jejunal MPO activity (unit/g of total protein) in Nr1i2+/+ and Nr1i2−/− mice treated
with indomethacin (n=6 per group).
(C) Histological score measuring severity of tissue damage in jejunum from Nr1i2+/+ and
Nr1i2−/− mice in indomethacin treated and untreated groups (n=6 per group).
(D) Weight to length ratio of the jejunum (enteropooling) in Nr1i2+/+ and Nr1i2−/− mice
treated with anti-CD3 antibody. The change in weight-to-length ratio in Nr1i2+/+ and
Nr1i2−/− mice exposed to anti-CD3 was 27.6% and 22.9%, respectively. Values represent
mean ± s.e.m. (n=5 per group). (E) Hematoxylin and eosin staining of anti-CD3 antibody
treated Nr1i2+/+ and Nr1i2−/− mice jejunum cross-sections.
(F) Serum FITC-dextran recovery following gastrointestinal ischemia-reperfusion (I/R)
injury in Nr1i2+/+ and Nr1i2−/− mice (n=5 per group). The change in permeability as
assessed by a change in recovery of mean levels of FITC - dextran in the serum of Nr1i2+/+
and Nr1i2−/− mice was 193% and 488.9%, respectively.
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(G) Kaplan-Meier survival curves of Nr1i2+/+ and Nr1i2−/− mice treated with LPS (n=6 per
group).
All graphs show mean values ± s.e.m. *P ≤ 0.02; **P ≤ 0.0001 (Two-way ANOVA with
Tukey’s multiple comparison test ). Scale bars, 50 μm. Also see Figure S3.
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Figure 4. Ultra-structural and functional defects in Nr1i2−/− mice small intestine
(A and B) Representative TEM images of Nr1i2+/+ (A) and Nr1i2−/− (B) mice jejunum
shows loose packing of microvilli in Nr1i2−/− mice. γ represents packing angle between
adjacent microvilli. Packing of microvilli in Nr1i2+/+ and Nr1i2−/− mice jejunum was
quantified by assessing the packing angle (γ) between adjacent microvilli. γ in Nr1i2−/−
mice cross-sections (81.0 ± 23.6°, n=273) is significantly higher and more variable
compared to Nr1i2+/+ mice (59.6 ± 7.0°, n=275) (n=5 per group).
(C) Sucrase, maltase, lactase and dipeptidyl peptidase (DPPIV) enzyme activities in
Nr1i2+/+ and Nr1i2−/− mice jejunum villi enterocytes. Proportionality between amount of
enzyme present (jejunal villi enterocyte homogenate containing 20 mg/ml of protein as
enzyme, x-axis) and amount of substrate liberated (optical density, y-axis) in 60 minutes was
plotted in the graph (n=8-10 per group).
(D) Alkaline phosphatase enzyme activity in Nr1i2+/+ and Nr1i2−/− mice jejunum villi
enterocyte homogenate (n=8-10 per group).
(E) Immunoblot analysis of alkaline phosphatase and β-actin (loading control) in Nr1i2+/+
and Nr1i2−/− mice jejunum villi enterocytes (n=5 per group).
(F) Representative TEM images of Nr1i2+/+ and Nr1i2−/− mice jejunum enterocytes
demonstrating cell-cell junctional complexes and perijunctional cytoskeletal condensation.
Inset shows magnified views of cell-cell junctional complex.
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(G) Real-time qPCR analysis of key Tj and Aj regulatory genes in Nr1i2+/+ and Nr1i2−/−
mice jejunum villi enterocytes (n=8-10 per group). Data plotted as fold change in Nr1i2−/−
mice relative to mRNA levels in Nr1i2+/+ mice.
(H) Serum FITC-dextran recovery in Nr1i2+/+ and Nr1i2−/− mice following treatment with
KDO2. (n=8-10 per group).
All graphs show mean values ± s.e.m.* , **P ≤ 0.0001; n.s. not significant (Two-way
ANOVA with Tukey’s multiple comparison test). Scale bars: A, B and F, 0.5 μm. Also see
Figure S4.
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Figure 5. Small intestine epithelial barrier dysfunction in Nr1i2−/− mice requires TLR4
expression and signaling
(A and B) Real-time qPCR analysis of (A) anti-inflammatory, anti-microbial, pro-
inflammatory and (B) Tlr gene expression in Nr1i2+/+ and Nr1i2−/− mice jejunum villi
enterocytes (n=8-10 per group). Data plotted as fold change in Nr1i2−/− mice relative to
mRNA levels in Nr1i2+/+ mice.
(C) Immunoblot shows increased expression of TLR4 in Nr1i2−/− mice (n=6 per group)
(left). Immunoblots are representative of three independent experiments. Quantitation of
band density was performed with two blots each with three different exposure times (right).
(D) Real - time qPCR analysis of key regulatory genes of epithelial barrier function in
Nr1i2+/+, Nr1i2−/−, Tlr4−/− and Nr1i2−/− /Tlr4−/− mice jejunum villi enterocytes (n=8-10
per group).
(E) Representative TEM images of Nr1i2+/+, Nr1i2−/−, Tlr4−/− and Nr1i2−/− / Tlr4−/− mice
jejunum showing microvilli (left) and quantitation of average microvillus length (right).
(F) Representative TEM images of Nr1i2+/+, Nr1i2−/−, Tlr4−/− and Nr1i2−/− / Tlr4−/− mice
jejunum showing cell-cell junctional complex.
(G) Enzyme (as denoted) activity assays performed with jejunal villi enterocyte homogenate
from Nr1i2+/+, Nr1i2−/−, Tlr4−/− and Nr1i2−/− /Tlr4−/− mice. Data are expressed as fold
change relative to Nr1i2+/+ mice.
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(H) Serum FITC-dextran levels in Nr1i2+/+, Nr1i2−/−, Tlr4−/− and Nr1i2−/− /Tlr4−/− mice
(n=8-10 per group). All graphs show mean values ± s.e.m. *P ≤ 0.05; **P ≤ 0.01; n.s. not
significant (A,B,D,E,G,H) (Two-way ANOVA with Tukey’s multiple comparison test); (C)
Student t-test. Scale bars: E and F, 0.5 μm. Also see Figure S5.
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Figure 6. TLR4 is critical for indomethacin-induced intestinal injury as well as IPA effects on
permeability in vivo
(A) Representative Hematoxylin and eosin staining of vehicle (-Indo) and indomethacin
(Indo) treated Nr1i2−/− /Tlr4−/− mice jejunum cross-sections (n=6 per group).
(B) Jejunal MPO activity (unit/g of total protein) in Nr1i2−/− and Nr1i2−/− /Tlr4−/− mice
treated with indomethacin (n=6 per group). *P ≤ 0.005 (One-way ANOVA with Sidak’s
multiple comparison test).
(C) Serum FITC-dextran recovery following oral gavage of IPA (20 mg/kg/day) and
indomethacin (see schematic ) in Tlr−/− (n = 9) mice.
(D) Serum FITC-dextran recovery following oral gavage of IPA (20 mg/kg/day) and KDO2
200μg/day (see schematic) in conventional mice (Nr1i2+/+ ) and commensal depleted (CD)
mice (Nr1i2+/+ ) (n = 8 per group). All graphs show mean values ± s.e.m. *P ≤ 0.004 ,**P ≤
0.05; n.s. not significant (Two-way ANOVA with Tukey’s multiple comparison test).
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Figure 7. Epithelial barrier defects in Nr1i2−/− mice small intestine is dependent on non-
hematopoietic (epithelium) compartment
(A and B) Real-time qPCR analysis of pro-inflammatory markers (A) Tnf-α and (B) Il-6 was
assessed in Nr1i2+/+ (n=10), Nr1i2−/− (n=10), Nr1i2+/+ BM→ Nr1i2+/+ (n=9), Nr1i2+/+
BM→ Nr1i2−/− (n=9), Nr1i2−/− BM→ Nr1i2+/+ (n=6) and Nr1i2−/− BM→ Nr1i2−/− (n=5)
mice jejunal villi enterocytes. Data are expressed as fold change in all mice groups
compared to Nr1i2+/+ mice.
(C) In vivo FITC-dextran permeability assay was performed in Nr1i2+/+ (n=10 mice),
Nr1i2−/− (n=10), Nr1i2+/+ BM→ Nr1i2+/+ (n=9), Nr1i2+/+ BM→ Nr1i2−/− (n=9),
Nr1i2−/− BM→ Nr1i2+/+ (n=6) and Nr1i2−/− BM→ Nr1i2−/− (n=5) mice.
(D) Real-time PCR analysis of proinflammatory markers (blue) Tnf-α and (red) Il-6 was
assessed in genotypes illustrated (n=5) mice jejunal mucosa. Data are expressed as fold
change in all mice groups compared to Nr1i2−/− /Tlr4+/+→ Nr1i2+/+ /Tlr4+/+ mice.
(E) In vivo FITC-dextran permeability assay was performed in (n=5) mice jejunal mucosa.
All graphs show mean values ± s.e.m.; n.s. not significant (Two-way ANOVA with Tukey’s
multiple comparison test).
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